【正文】 s[J].Lupus，2007，16(2)：121.[2] Remer CF, Weisman MH, Wallace of leflunomide in systemic lupus erythematosus: a pilot observational study[J].Lupus, 2001,10:480.[3] Mok CC, Tong KH, To CH, et for induction therapy of diffuse proliferative lupus nephritis: an openlabeled pilot study[J].Kidney Int, 2005,68:813.[4] Chan TM, Li FK, Tang CS, et of mycophenolate mofetil in patients with diffuse proliferative lupus KongGuangzhou Nephrology Study Group[J].N Engl J Med, 2000,343:1156.[5] Hu W, Liu Z, Chen H, et mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis[J].Chin Med J(Engl), 2002,115:705.[6] AlarconSegovia D, Tumlin JA, Furie RA, et 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, doubleblind, placebocontrolled study[J].Arthritis Rheum, 2003,48:442.[7] Sfikakis PP, Boletis JN, Lionaki S, et of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: an openlabel trial[J].Arthritis Rheum, 2005,52:501.[8] Seshasayee D, Valdez P, Yan M, et of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor[J].Immunity, 2003,18:279.[9] Boumpas DT, Furie R, Manzi S, et short course of BG9588(antiCD40 ligand antibody)improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis[J].Arthritis Rheum, 2003,48:719.[10] Kalunian KC, Davis JC Jr, Merrill JT, et of systemic lupus erythematosus by inhibition of T cell costimulation with antiCD154: a randomized, doubleblind, placebocontrolled trial[J].Arthritis Rheum, 2002,46:3251.[11] Larsen CP, Pearson TC, Adams AB, et development of LEA29Y(belatacept), a highaffinity variant of CTLA4Ig with potent immunosuppressive properties[J].Am J Transplant, 2005,5:443.[12] Daikh DI, Wofsy edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide[J].J Immunol, 2001,166:2913.[13] Pittenger MF, Mackay AM, Beck SC, et potential of adult human mesenchymal stem cells[J].Science, 1999,284(5411):143.[14] Koc ON, Gerson SL, Cooper BW, et hematopoietic recovery after coinfusion of autologousblood stem cells and cultureexpanded marrow mesenchymal stem cells in advanced breast cancer patients receiving highdose chemotherapy[J].J Clin Oncol, 2000,18(2):307.[15] Di Nicola M, CarloStella C, Magni M, et bone marrow stromal cells suppress Tlymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[J].Blood, 2002,99(10):3838.[16] Tse WT, Pendleton JD, Beyer WM, et of allogeneic Tcell proliferation by human marrow stromal cells: implications in transplantation[J].Transplantation, 2003,75(3):389.[17] Le Blanc K, Tammik L, Sundberg B, et stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histopatibility plex[J].Scand J Immunol, 2003,57(1):11.[18] Djouad F, Plence P, Bony C, et effect of mesenchymal stem cells favors tumor growth in allogeneic animals[J].Blood,2003,102(10):3837.[19] Bartholomew A, Sturgeon C, Siatskas M, et stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo[J].Exp Hematol, 2002,30(1):42.[20] Le Blanc K, Rasmusson I, Sundberg B, et of severe acute graftversushost disease with third party haploidentical mesenchymal stem cells[J].Lancet, 2004,363(9419):1439.[21] Le Blanc K, Tammik C, Rosendahl K, et expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells[J].Exp Hematol, 2003,31(10):890.[22] Morton JI, Siegel of autoimmune of antinuclear antibodies in H2 histopatible recipients of bone marrow from New Zealand Black mice[J].Proc Natl Acad Sci U S A, 1974,71(6):2162.[23] Ikehara S, Good RA, Nakamura T, et for bone marrow transplantation in the treatment of autoimmune diseases[J].Proc Natl Acad Sci U S A, 1985,82(8):2483.[24] Papadaki HA, Boumpas DT, Gibson FM, et apoptosis of bone marrow CD34+ cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus[J].Br J Haematol, 2001,115(1):167.[25] Ikehara strategies for allogeneic BMT[J].Bone Marrow Transplant, 2003,32(1):73.[26] 李 慧，[J].中華醫(yī)學雜志，2006，86：【關鍵詞】 慢性咽炎。治療慢性咽炎是耳鼻喉科常見病之一，單純用西藥治療往往效果不佳。臨床資料 病例選擇 147例患者中，女82例，男65例。其中干燥性咽炎24例，慢性單純性、肥厚性、慢性粒性咽炎123例，病程時間不等。另外長期受化學氣體、粉塵、濁氣的刺激，嗜食煙酒辛辣也是造成虛火喉痹的主要誘因，治宜滋陰清熱。局部配合霧化吸入治療或含漱及激光治療。對于咽部有異物感，有時癢痛、咳痰，檢查咽部黏膜慢性充血，側索增厚，有淋巴濾泡增生，咽后壁有粘性分泌物附著則采用中藥方劑：元參、金銀花、桔梗、貝母、甘草、胖大海、梔子，便秘者加柏子仁、瓜蔞。憋悶、咽干似有痰不易咳出，治療后癥狀消失的比例占76%。 從體征的改善情況分析 淋巴濾泡增生及側索腫脹的，治療后淋巴濾泡明顯減少者的比例占73%。體會筆者在臨床觀察中發(fā)現(xiàn)咽部疾病與周身各部有著廣泛聯(lián)系。此外更年期、神經衰弱也占一定比例，由于內分泌和神經的失調，使病人有多種癥狀，咽部癥狀是其中之一，因此多需精神療法及中西醫(yī)結合治療解除其病癥。四味散對慢性化膿性中耳炎的作用發(fā)表時間：2010729 11:19:50 瀏覽次數(shù)：2145 來源：創(chuàng)新醫(yī)學網推薦【摘要】 慢性化膿性中耳炎主要是急性化膿性中耳炎未能及時治愈，拖延6周以上者，是中耳的慢性化膿性炎癥，病變侵及中耳黏膜、骨膜或深達骨質，常合并存在慢性乳突炎。【關鍵詞】 四味散。作用[Abstract] Chronic suppurative otitis media monly was known as “stinky ears fundamentals”, mainly was acute suppurative otitis media which was failed to cure, delayed for more than six weeks is easy to be a chronic middle ear purulent inflammation, lesion invaded in the middle ear mucosa, periosteum or deep up bone, often bined with chronic mastoiditis with tinnitus, earache, headache, dizziness, pus, and even disappearance of symptoms such as hearing loss.[Key words] Siweisan powder。effect慢性化膿性中耳炎是急性化膿性中耳炎未能及時治愈，拖延6周以上者，是中耳的慢性化膿性炎癥，病變侵及中耳黏膜、骨膜或深達骨質，常合并存在慢性乳突炎。(2)壞死型：炎癥已浸潤到骨質，耳內流出物如干酪樣(豆渣樣)，量少，有臭味。資料與方法 一般資料 本組病例男68例，女39例。單純型12例，壞死型68例，膽脂瘤型27例。 功效(1)五倍子藥性酸、澀、寒?！侗静菥V目》：“斂肺降火，化痰飲，止咳嗽、消渴、盜汗、嘔吐、失血、久痢?！薄捌湮端嵯?，能斂肺止血，化痰止渴收。其性收，能除瀉痢濕爛。具有清熱解毒，涼血消斑，瀉肝清肺祛暑定驚之功。亦摩敷熱瘡。”(3)冰片藥性辛、苦、微寒。故外用清熱消腫、消腫、止痛、生肌斂瘡?！?4)朱砂藥性甘，微寒?！?用法 將五倍子、冰片研末，然后將四味藥混合在一起，混勻。取1部分藥，將其吹入耳中，藥量適中，不要太多。有效：流膿、耳鳴、耳痛、頭痛、頭暈等癥狀消失，但聽力無好轉者。 治療結果 單純型12例，顯效8例，有效3例，無效1例，總有效率92%。膽脂瘤型27例，顯效11例，有效14例，無效2例，總有效率92%。不僅給患者帶來身心上的痛苦，更嚴重是對聽力的損害。青黛能清熱解毒，并對細菌有抑制和殺滅作用，冰片能消腫、止痛、防腐生肌及殺滅細菌，朱砂也能解毒。對耳膜